The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
2.
ISOLATED GLIAL PROGENITOR CELLS FOR USE IN THE COMPETITION TREATMENT OF AGE-RELATED WHITE MATTER LOSS
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 27/00 - Médicaments pour traiter les troubles des sens
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
3.
HUMANIZED CHIMERAS FOR THE PROSPECTIVE ASSESSMENT OF GLIAL CELL ADDITION OR REPLACEMENT THERAPY
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
A METHOD FOR DETERMINING A CHARGE-STATE BOUNDARY OF A QUANTUM DOT, A MULTI-DOT DEVICE, OR AN ARRAY OF QUANTUM DOTS AND A DATA PROCESSING SYSTEM FOR PERFORMING THE METHOD
The invention regards a method for determining a charge-state boundary of a quantum dot, a multi-dot device, or an array of quantum dots, comprising the steps of defining an initial point inside a charge state of a quantum dot having a charge-state boundary, ramping gate voltages from the initial point thereby creating a plurality of rays in gate voltage space, creating a time stamp when each of the rays leave the charge-state / cross the charge-state boundary, and constructing the boundary of the charge state by correlating each ray in gate voltage space with the associated time stamp.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
5.
ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP)
The present invention relates to humanized antibodies and molecular conjugates targeting Urokinase type plasminogen activator receptor associated protein (uPARAP), in particular antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as certain cancers.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).
The present invention relates to mutant Cas12j (also known as Cas?) endonucleases having altered activity or improved properties compared to the corresponding wild type Cas12j endonuclease, as well as methods using the mutant Cas12j endonucleases.
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (Allemagne)
ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (Allemagne)
Inventeur(s)
Kjaer, Andreas
Herth, Matthias Manfred
Jensen, Andreas Ingemann
Eder, Matthias
Eder, Ann-Christin
Abrégé
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate?specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase ? 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
16.
POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR
The present invention relates to non-naturally occurring antibodies or active antibody fragments specifically binding the calcium-sensing receptor (CaSR), acting as positive allosteric modulators (PAMs) to provide for potent therapeutic agents. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal a novel therapeutic strategy to reduce parathyroid hormone release in a subject, and are therefore suitable for treatment of hypercalcemia disorders. Moreover, co-application of such an ISVD and a synthetic PAM or calcimimetic results in a synergistic agonistic CaSR activity providing for pharmaceutical compositions as next generation CaSR drugs.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
The present invention describes a uPAR-targeting peptide conjugate comprising a fluorophore, a peptide binding to uPAR and a linker group which are connected by covalent bonds, wherein the uPAR-targeting peptide conjugate may be used as fluorescence probe in real time optical imaging and delineation of cancer tumors or metastases during surgery.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
19.
TREATMENT OF CNS DISORDERS WITH SLEEP DISTURBANCES
A compound for use in the treatment of CNS disorders with sleep disturbances e.g. narcolepsy or Angelman syndrome in a subject, wherein said compound is according to formula (I) or any isomer, tautomer, enantiomer, racemic form or deuterated form thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
20.
INHIBITION OF RE1-SILENCING TRANSCRIPTION FACTOR IN THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS
The present disclosure is directed to methods of restoring glial cell K+ uptake in a subject. This method involves selecting a subject having impaired glial cell K+ uptake, and administering, to the selected subject, a REI-Silencing Transcription factor (REST) inhibitor to restore glial cell K+ uptake. Subjects having impaired glial cell K+ uptake include those at risk of having or having a neuropsychiatric disease or disorder.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
21.
METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE
The disclosure herein relates generally to a method of treating or inhibiting onset of Huntington's disease. This method involves selecting a subject having or at risk of having Huntington's disease and administering to the subject one or modulators of one or more genes as described herein, or proteins encoded therefrom, under conditions effective to treat or inhibit onset of Huntington's disease in the subject.
The present invention relates to mutant Cpf1 endonucleases having altered activity compared to the wild type Cpf1, and their use to introduce single strand breaks in nucleic acid sequences. Methods for detection and quantification of a nucleic acid sequence are also disclosed. Methods for diagnosis of an infectious disease are also disclosed.
A subject's level of soluble urokinase type plasminogen activator (suPAR) is checked as part of a risk stratification procedure in a hospital emergency department to help decide whether to admit the subject to the hospital, keep the subject in as a patient, or discharge a patient.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
24.
COMPOSITE COMPRISING GREEN RUST AND CARBON FOR ENVIRONMENTAL REMEDIATION
The invention regards a composite for environmental remediation, comprising: - one or more green rust compound(s) or green rust precursor(s), and - one or more biochar(s).
The present disclosure relates to methods of generating glucose-responsive, insulin- producing beta cells, populations of insulin-producing beta cells obtained by said methods, and the use of said populations for treatment of a metabolic disorder in an individual in need thereof.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
A61K 35/39 - Appareil digestif Îlots de Langerhans
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspension; Leur conservation; Milieux de culture à cet effet
A method for obtaining a betalain pigment composition from red beet plants comprising pre-harvest foliar spraying of an ethylene-generating compound and the use of the ob- tained betalain pigment composition for coloring of an edible product.
A23L 5/43 - Adjonction de colorants ou de pigments, p.ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés
A23K 20/179 - Agents colorants, p.ex. agents de pigmentation ou de teinture
C09B 61/00 - Colorants naturels préparés à partir de sources naturelles
The invention relates to a method for controlling of a biofilm, for removing of a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process comprising cellulosic fibre material. In the method a composition comprising a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2- propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.
Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIP5-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co- amorphous form.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.
The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.
The present invention relates to a mechanical resonator device. The resonator device comprises a resonator element made of an elastic material under tensile stress and adapted for sustaining at least one oscillation mode; and a clamping structure supporting the resonator element. The clamping structure has a phononic density of states exhibiting a bandgap or quasi-bandgap such that elastic waves of at least one polarisation and/or frequency are not allowed to propagate through the clamping structure. The resonator element and the clamping structure are configured to match with a soft-clamping condition that elastic waves of polarisation and/or frequency corresponding to the at least one oscillation mode of the resonator penetrate evanescently into the clamping structure in a manner such as to minimize bending throughout the entire resonator device. Thereby, bending related loss may be minimized and the Q-factor of the mechanical resonator may be maximized.
G01G 3/16 - Appareils de pesée caractérisés par l'utilisation d'organes déformables par élasticité, p.ex. balances à ressort dans lesquels l'élément de pesée est constitué par un corps solide soumis à une pression ou une traction pendant la pesée utilisant la mesure des variations de la fréquence des oscillations du corps
G01N 29/036 - Analyse de fluides en mesurant la fréquence ou la résonance des ondes acoustiques
H03H 9/02 - Réseaux comprenant des éléments électromécaniques ou électro-acoustiques; Résonateurs électromécaniques - Détails
H03H 9/24 - Réseaux comprenant des éléments électromécaniques ou électro-acoustiques; Résonateurs électromécaniques - Détails de réalisation de résonateurs en matériau qui n'est ni piézo-électrique, ni électrostrictif, ni magnétostrictif
The invention relates to methods for preparing a beverage comprising at least 2 g/L ß-glucan, wherein said ß-glucans have an average molecular weight in the range of 80 to 200 kDa. The methods involve mashing barley kernels comprising at least 10% ß-glucans and having a ratio of DP3/DP4 in said ß-glucan of at least 3 in the presence of a-amylase and endo-1,3(4)-ß-glucanase activity. The beverages have a viscosity providing a good mouth-feel, and at the same time they comprise ß-glucans, which are able to aid in lowering LDL cholesterol levels. The beverages are generally stable and can be stored for months at room temperature without a significant decrease in ß-glucan content.
The present invention relates to conjugates targeting uPARAP, in particular antibody- drug conjugates (ADCs) comprising monoclonal antibodies directed against the N- terminal region of uPARAP,and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present disclosure relates to a method for producing a network of interconnected nanostructures comprising the steps of: providing a substantially plane substrate; growing a plurality of elongated nanostructures from the substrate; kinking the growth direction of at least a part of the nanostructures such that at least part of the kinked nanostructures are growing in a network plane parallel to the substrate, and creating one or more network(s) of interconnected kinked nanostructures in the network plane, wherein a dielectric support layer is provided below the network plane to support said network(s) of interconnected nanostructures.
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
38.
DIESEL-SOLUBLE LIGNIN OILS AND METHODS OF THEIR PRODUCTION
Solvent consumption in supercritical ethanol, propanol or butanol treatment of either refined pre-extracted lignin or comparatively impure lignin-rich solid residual from hydrothermally pretreated lignocellulosic biomass can be minimized by conducting the reaction at very high loading of lignin to solvent. Comparatively impure, crude lignin- rich solid residual can be directly converted by supercritical alcohol treatment to significantly diesel-soluble lignin oil without requirement for pre-extraction or pre- solubilisation of lignin or for added reaction promoters such as catalysts, hydrogen donor co-solvents, acids, based or H2 gas. O:C ratio of product oil can readily be obtained using crude lignin residual in such a process at levels 0.20 or lower.
C10G 1/04 - Production de mélanges liquides d'hydrocarbures à partir de schiste bitumineux, de sable pétrolifère ou de matières carbonées solides non fusibles ou similaires, p.ex. bois, charbon par extraction
C10G 3/00 - Production de mélanges liquides d'hydrocarbures à partir de matières organiques contenant de l'oxygène, p.ex. huiles, acides gras
C10L 1/02 - Combustibles carbonés liquides à base essentielle de composants formés uniquement de carbone, d'hydrogène et d'oxygène
C10L 1/08 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures pour allumage par compression
39.
VIRUS-LIKE PARTICLE WITH EFFICIENT EPITOPE DISPLAY
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques
40.
A SEMICONDUCTOR JOSEPHSON JUNCTION AND A TRANSMON QUBIT RELATED THERETO
The present disclosure relates to semiconductor based Josephson junctions and their applications within the field of quantum computing, in particular a tuneable Josephson junction device has been used to construct a gateable transmon qubit. One embodiment relates to a Josephson junction comprising an elongated hybrid nanostructure comprising superconductor (Al) and semiconductor (InAs) materials and a weak link, wherein the semiconductor weak link is formed by a semiconductor segment of the elongated hybrid nanostructure where the superconductor material has been removed.
An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.
Processes for producing cellulose microfibrils from herbaceous plant material using enzyme compositions, the cellulose microfibrils obtained from the processes and their uses, and compositions comprising the cellulose microfibrils are described.
The invention relates to methods for producing vanillin and related compounds. The methods involve use of a vanillin synthase capable of catalyzing side chain cleavage of ferulic acid to form vanillin. The invention also relates to host organisms expressing such vanillin synthases useful in the methods.
This invention relates to methods for the detection of a bovine that is affected by or carrier of brachyspina. It is based on the identification of a 3.3 Kb deletion in the bovine FANCI gene that is shown to cause the brachyspina syndrome. The present invention provides methods and uses for determining whether a bovine is affected by or carrier of brachyspina by analyzing its genomic DNA or its RNA. The methods can be used to perform marker assisted selection or genomic selection for increased fertility in said bovine.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
45.
GLUCOSINOLATE TRANSPORTER PROTEIN AND USES THEREOF
Methods and means to alter the glucosinolate (GSL) content in plants, in particular in specific plant parts, by modifying glucosinolate transporter protein (GTR) activity in plants or parts thereof are herein described. In particular, methods are provided to decrease GSL content of plant seed and meal thereof, as well as methods to increase GSL content in green plant tissue, of Brassicales plants.
The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present invention relates to methods for reducing fat uptake in the gastrointestinal tract of a mammal in order to prevent a positive energy balance, weight gain, overweight and obesity, and to induce a negative energy balance and weight loss in subjects who wish to reduce their body weight. In particular, food and/or beverage ingredients and dietary supplements of the present invention comprises flaxseeds useful for increasing faeca fat excretion from the gastrointestinal tract.
brevets
